Optiscan Imaging Limited · ASX:OIL
Optiscan Imaging — Shareholder Meeting (November 2002)
26 slides from Optiscan Imaging's shareholder meeting presentation, Nov 13, 2002

Slide 1: Optiscan Imaging Limited Annual General Meeting 13th Nov 2002
Optiscan Imaging Limited Annual General Meeting 13th Nov 2002 Unlocking the world of Live Micro Imaging (LMI) technology

Slide 2: Managing Director's Address
Optiscan Imaging Limited Annual General Meeting 13th Nov 2002 Managing Director’s Address Unlocking the world of Live Micro Imaging (LMI) technology

Slide 3: Today's Presentation Will Cover
TODAYS PRESENTATION WILL COVER • A brief review of our technology and products • Review of operations by product group • Financial Outlook

Slide 4: Live Micro Imaging (LMI)
Live Micro Imaging (LMI) • In vivo microscopy • Miniaturised devices • Immediate imaging of live cells • Microscopic, sub-cellular view (~1000x) • Non-invasive: no surgical removal of tissue • Live computer screen image • Internet ready • Anticipated long term cost savings

Slide 5: Patented Fibre Optic Confocal System
Patented Fibre Optic Confocal System Detector Scan mechanism Beamsplitter Laser (**Patented) Optical fibre Objective (**Patented) Specimen Focal plane

Slide 6: Patented Miniaturised Scanner
Patented Miniaturised Scanner • Key to Flexible Endoscopes 43mm 5mm

Slide 7: Confocal Imaging Applications
Confocal Imaging Applications Trachea Liver Respiratory epithelium Hepatocytes Skin Lesions Kidney Colon Cortex Crypt Abnormalities Bladder Cervix Orthopaedics/Joints Epithelium and connective tissue Squamous epithelium Knee Cartilage: Chondrocytes

Slide 8: Instrument Development Pipeline
Instrument Development Pipeline Rigid Endoscopes for... O&G (cervix) Head & Neck Orthopaedics Clinical Trial Grade Prototypes Flexible endoscope Colonoscopy Gastroscopy Marketed by Pentax Stratum FDA exempt, TGA listed Benchtop Systems Licensed to six international manufacturers Commercial in Confid

Slide 9: Introduction of new medical devices
Introduction of new medical devices • Step 1 – Pre-sales marketing and preliminary “proof of concept” clinical work • Step 2 - Regulatory clearance (FDA) • Step 3 - Establishment with market opinion leaders • Step 4 - Initial sales to early adopters • Step 5 - Maturation of applications and promotio

Slide 10: Strategic Priorities
Strategic Priorities 1. Flexible endoscopy • Via Pentax partnership 2. Rigid endoscopy • Partnering for commercialisation 3. Stratum • Focus on sales into research market

Slide 11: Flexible Endomicroscope
Flexible Endomicroscope • Subject of Pentax Agreement • Colon Cancer • Ulcerative Colitis • Gastric Cancer • No change in user workflow • Unique capability

Slide 12: LMI of Human Colon
LMI of Human Colon Conventional Endoscope LMI of Normal Human Colon

Slide 13: Pentax Joint Venture
Pentax Joint Venture • Optiscan and Pentax to jointly develop flexible endoscope with integrated microscope • Pentax will exclusively market the system world-wide • Optiscan supplies key components, Pentax will perform the final manufacturing • Rigid endoscopes and hand-held skin endoscopes are not

Slide 14: Pentax Joint Venture
Pentax Joint Venture • Initial payment - A$6.5 million (banked). • Placement - A$6.5 million for 3.33 million shares in Optiscan at A$1.92 (US $1.00). Completed in April. • Milestone – A$6.5 million on successful completion of the development phase. • Significant ongoing royalties and manufacturing

Slide 15: Rigid Endoscopes
Rigid Endoscopes • Gynaecology • Ear, Nose & Throat • Orthopaedics Arthroscope • Head and Neck • Urology • Keyhole surgery Proctoscope

Slide 16: LMI of Normal and Diseased Cervix
LMI of Normal and Diseased Cervix •Royal Women’s Hospital Clinical Evaluation: •Associate Professor Michael Quinn •Dr Jeffrey Tan Normal Epithelium Cervical Neoplasia FOV = 400 µm

Slide 17: Other Active Rigid Endoscopy Applications
Other Active Rigid Endoscopy App’s •Head and Neck – National Cancer Centre, Singapore •Professor Soo Khee Chee (Head, Department of Surgery) •Dr Malini Olivo (Photobiologist) •Initiated clinical evaluation this month •Orthopaedics – University of Western Australia •Professor David Wood (orthopaedic

Slide 18: Rigid Endoscopes - Commercialisation
Rigid Endoscopes - Commercialisation • Continue clinical evaluations • Utlilise clinical data to interest key partners in relevant market segments • Partner for sales, distribution and possibly manufacturing

Slide 19: Optiscan Stratum
Optiscan Stratum • Dermatology research • Skin Cancer • Psoriasis • Inflammatory Lesions • Pharmaceuticals • Cosmetics • FDA exempt - class I medical examination device • List Price - approx. US $75,000

Slide 20: Clinical & Research Partners
Clinical & Research Partners • Reference Sites • USA Memorial Sloan-Kettering Cancer Center (NY) Medical College of Wisconsin (WI) University of California, Davis (CA) University of Pittsburgh (PA) • Europe Linkoping University Hospital, (Sweden) • Australia Gold Coast Skin Centre (QLD) • Cutaneous

Slide 21: Competition in Tissue Microscopy
Competition in Tissue Microscopy Optiscan Competing Comments Product products Stratum Vivascope by Lucid Not highly miniaturised; Complementary in market development. Flexible None Others are researching endomicroscope fibre confocal probes; we believe that patent infringement = barrier to entry. Ri

Slide 22: Consumables & Disposables
Consumables & Disposables • Contrast Agents • Fluorescent Agents which increase contrast • So far, using common clinical agents • Would be packaged for single procedure • Under consideration with dye manufacturers • Not yet a product • Sheaths/tips • Some procedures require sterile tips • e.g. Rigid

Slide 23: Operating Result & Outlook
Operating Result & Outlook • Net loss before tax 30 June 2002: $1.817M • Improvement of $2.873M (61%) on 2201 loss of $4.69M • June 2002 balance - AUD$16m • Final Pentax Payment AUD $6.5M achievable • Royalty income from licenses expected to be $800K • Have budgeted 11 sales to Pentax • Have budgete

Slide 24: Share price performance
Share price performance • Factors • Re-rating of biotech stocks • Optiscan’s performance is comparable with decline of biotechs on NASDAQ • Stratum sales have been disappointing • What are we doing to improve it? • Perform • Pentax • Communicate

Slide 25: Summary
Summary • Flexible Endoscopy & Pentax Partnership • Joint development resources • Access to global sales and marketing network • Secured sound financial position • Further AUD$6 Million milestone payment to come • Rigid Endoscopy – a third product group • 2 new areas of application in clinical evalu

Slide 26: www.Optiscan.com
www.Optiscan.com Unlocking the world of Live Micro Imaging (LMI) technology
Source: Internet Archive copy of optiscan.com
More decks from Optiscan Imaging Limited
Bell Potter Healthcare Conference (November 2026)11 slides · Nov 17, 2026
Investor Presentation (December 2025)37 slides · Dec 4, 2025
Shareholder Meeting (November 2025)40 slides · Nov 14, 2025
ASX SMIDcaps Conference, Sydney 202522 slides · Sep 24, 2025
Corporate Update (April 2025)26 slides · Apr 10, 2025
TSN ASX Gems Conference (March 2025)16 slides · Mar 28, 2025